Enanta Pharmaceuticals | ENTA - 债务





债务 更改 日
AbbVie USD 67.5B 67.5B 2025-12
Amgen USD 54.6B 17M 2025-12
Anika Therapeutics USD 0 0 2025-03
Arrowhead Research USD 366.28M 13.25M 2025-09
AstraZeneca USD 33.92B 4.3B 2026-03
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Biogen USD 6.56B 275.1M 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Gilead Sciences USD 24.94B 5M 2025-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Heron Therapeutics USD 149.65M 157K 2024-09
Immunic USD 0 0 2024-06
Incyte USD 39.43M 982K 2026-03
Insmed USD 727.89M 163.33M 2025-12
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
J&J USD 47.93B 2.14B 2025-12
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Ligand Pharmaceuticals USD 451M 445.26M 2025-09
Merck USD 49.34B 7.97B 2025-12
Neurocrine Biosciences USD 415.3M 13.1M 2025-12
Novartis USD 47B 11.62B 2026-03
Novavax USD 233.31M 4.23M 2024-09
Pfizer USD 63.96B 3.11B 2025-12
PTC Therapeutics USD 2.71B 2.42B 2025-12
Roche Holding CHF 33.03B 1.41B 2025-06
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
Vertex Pharmaceuticals USD 2.03B 195.7M 2025-12